| Literature DB >> 35365662 |
Silvia Gervasoni1, Giuliano Malloci2, Andrea Bosin1, Attilio V Vargiu1, Helen I Zgurskaya3, Paolo Ruggerone1.
Abstract
Antibiotic resistance is a major threat to public health. The development of chemo-informatic tools to guide medicinal chemistry campaigns in the efficint design of antibacterial libraries is urgently needed. We present AB-DB, an open database of all-atom force-field parameters, molecular dynamics trajectories, quantum-mechanical properties, and curated physico-chemical descriptors of antimicrobial compounds. We considered more than 300 molecules belonging to 25 families that include the most relevant antibiotic classes in clinical use, such as β-lactams and (fluoro)quinolones, as well as inhibitors of key bacterial proteins. We provide traditional descriptors together with properties obtained with Density Functional Theory calculations. Noteworthy, AB-DB contains less conventional descriptors extracted from μs-long molecular dynamics simulations in explicit solvent. In addition, for each compound we make available force-field parameters for the major micro-species at physiological pH. With the rise of multi-drug-resistant pathogens and the consequent need for novel antibiotics, inhibitors, and drug re-purposing strategies, curated databases containing reliable and not straightforward properties facilitate the integration of data mining and statistics into the discovery of new antimicrobials.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35365662 PMCID: PMC8976083 DOI: 10.1038/s41597-022-01261-1
Source DB: PubMed Journal: Sci Data ISSN: 2052-4463 Impact factor: 6.444
Fig. 1Schematic view of the computational protocol adopted to generate AB-DB. The different steps reporting some representative molecular descriptors are highlighted: molecular characterization, QM calculations, FF parameters generation, MD simulations. For further technical details see Methods section.
Fig. 2Schematic representation of four representative antimicrobials belonging to different classes, namely (a) penicillins, (b) (fluoro)quinolones, (c) aminoglycosides, and (d) aminocoumarins. Graphics rendered with DiscoveryStudio[101].
List of families and antimicrobial compounds included in AB-DB.
| Family | # | Compounds |
|---|---|---|
| Aminocoumarins | 8 | chlorobiocin, novobiocin, declovanillobiocin, isovanillobiocin, novclobiocin 101, plazomicin, |
| Aminoglicosides | 15 | |
| Anthracenediones | 2 | mitoxantrone, pixantrone |
| Anthracyclines | 4 | daunorubicin, doxorubicin, epirubicin, idarubicin |
| 11 | avibactam, bal0029880, clavulanic acid, durlobactam, enmetazobactam, nacubactam, relebactam, sulbactam, tazobactam, thienamycin, zidebactam | |
| Carbapenems | 14 | biapenem, doripenem, ertapenem, faropenem1, imipenem, LK-157, meropenem, olivanic acid, panipenem, razupenem, ritipenem, sanfetrinem, tebipenem, tomopenem |
| Cephalosporins | 39 | cefaclor, cefadroxil, cefalonium, cefamandole nafate, cefamandole sodium, cefazolin, cefdinir, cefditoren, cefepime, cefetamet, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotetan, cefoxitin, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefsulodin, ceftaroline, ceftazidime, ceftibuten, ceftizoxime, ceftobiprole, ceftriaxone, cefuroxime, cephalexin, cephaloridine, cephalotin, cephapirin, cephradine, |
| DHFR inhibitors | 7 | |
| Efflux pumps inhibitors | 9 | D13-9001, |
| Quinolones | 36 | cinoxacin, |
| Fusidanes | 2 | fusidica acid, helvolic acid |
| Lincosamides | 4 | clindamycin, |
| Macrolides | 9 | azithromycin, |
| Monobactams | 10 | aztreonam, BAL19764, BAL30072, carumonam, gloximonam, nacubactam, nocardicin, oximonam, pirazmonam, tigemonam |
| Nitrofurans | 12 | furazolidone, nifurfoline, nifurquinazol, nifurtoinol, nitrofurantoin, nitrovin, nifuratel, nifuroxazide, nifurtimox, nifurzide, nitrofurazone, tinidazole |
| Nucleosides | 4 | A-500359A, A-503083E, capuramycin, puromycin |
| Oxacephem | 2 | latamoxef, flomoxef |
| Oxazolidinones | 8 | contezolid, eperezolid, linezolid, posizolid, radezolid, ranbezolid, sutezolid, tedizolid |
| Penicillins | 20 | 6-APA, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, methicillin, mezlocillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, sulbenicillin, temocillin, ticarcillin |
| Phenicols | 5 | azidamfenicol, chloramphenicol, florfenicol, tevenel, thiamphenicol |
| Rifamycins | 2 | |
| Streptogramins | 1 | dalfopristin |
| Sulphonamides | 20 | sulfabenzamide, sulfacetamide, sulfachlorpyridazine, sulfadiazine, sulfadimethoxine, sulfaguanidine, |
| Tetracyclines | 10 | chlortetracycline, demeclocycline, doxycycline, meclocycline, methacycline, minocycline, omadacycline, oxytetracycline, tetracycline, tigecycline |
| Others | 20 | acriflavine, cycloserine, dapsone, deoxycholate, |
Boldface labels identify molecules for which two protonation states were considered. Molecules for which the PubChem 3D structure is not available are highlighted in italic. Column “#“ reports the total number of compounds for each family. 1Faropenem belongs to penems family, in AB-DB it is included in the carbapenems family.
Average experimental and predicted (boldface) pK values. Relative percentage error of computed pK value is reported in parentheses.
| Quinolones | |||||
|---|---|---|---|---|---|
| pK | pK | ||||
| ciprofloxacin[ | 6.29, | 8.26, | |||
| difloxacin[ | 5.98, | 7.75, | |||
| enoxacin[ | 6.57, | 7.17, | |||
| enrofloxacin[ | 6.01, | 7.93, | |||
| fleroxacin[ | 5.78, | 7.86, | |||
| lomefloxacin[ | 5.78, | 8.74, | |||
| norfloxacin[ | 5.97, | 8.42, | |||
| ofloxacin[ | 6.04, | 8.09, | |||
| pefloxacin[ | 6.45, | 7.84, | |||
| sarafloxacin [104] | 5.99, | 7.84, | |||
| levofloxacin[ | 5.6, | 7.9, | |||
| sulfamerazine[ | 2.15, | 6.82, | |||
| sulfamethazine[ | 2.24, | 7.51, | |||
| sulfathiazole[ | 2.05, | 7.14, | |||
| chlortetracycline[ | 3.64, | 6.57, | 8.64, | ||
| demeclocycline[ | 3.37, | 7.36, | 9.44, | ||
| doxycycline[ | 3.02, | 7.97, | 9.15, | ||
| meclocycline[ | 4.05, | 6.87, | 9.59, | ||
| oxytetracycline[ | 3.32, | 7.02, | 8.74, | ||
| tetracycline[ | 3.17, | 6.79, | 9.07, | ||
| amikacin[ | 9.89, | 7.64, | — | 8.81, | 8.05, |
| gentamicin C1[ | 7.67, | 6.19, | 7.4, | 9.86, | 8.78, |
| netilmicin[ | 8.15, | 6.52, | 8.15, | 9.32, | 8.48, |
| sisomicin[ | 7.43, | 6.21, | 8.01, | 9.31, | 8.50, |
| tobramycin[ | 7.56, | 6.70, | 7.75, | 9.11, | 7.71, |
| loracarbef[ | 6.84, | ||||
| trimethoprim[ | 7.50, | ||||
| rifampicin[ | 1.7, | 7.9, | |||
Fig. 3Graphical exemplification of the three types of analysis performed to generate AB-DB. Puromycin molecule has been selected as a test-case. QSAR: number of rotatable bonds (left), QM and FF: atomic partial charges (center), from negative (red) to positive (blue) values, MD: conformations extracted from MD trajectories (right). Graphics rendered with PyMOL[102].
Fig. 4Schematic representation of the AB-DB structure reporting filenames of each sub-directory.
Experimental logP (LogP exp) and LogP values computed by XLOGP3 and cxcalc.
| Family | Compound | LogP exp | XLOGP3 (%ERR) | LogP cxcalc (%ERR) |
|---|---|---|---|---|
| aminocoumarins | chlorobiocin | 5.15[ | 5.98 (16) | 4.94 (4) |
| novobiocin | 3.1[ | 3.96 (28) | 3.26 (5) | |
| streptogramins | dalfopristin | 2.57[ | 2.23 (13) | 1.58 (39) |
| macrolides | telithromycin | 2.1[ | 4.16 (98) | 5.05 (140) |
| penicillins | dicloxacill | 2.91[ | 3.78 (30) | 2.91 (0) |
| cloxacillin | 2.43[ | 3.15 (30) | 2.30 (5) | |
| oxacillin | 2.31[ | 2.53 (10) | 1.70 (26) | |
| penicillin G | 1.70[ | 1.95 (15) | 1.08 (36) | |
| methicillin | 1.896[ | 1.96 (3) | 0.79 (58) | |
| temocillin | 1.39[ | 2.4 (73) | 1.2 (14) | |
| quinolones | delafloxacin | 2.63[ | 2.76 (5) | 2.56 (3) |
| difloxacin | 0.84[ | 1.49 (77) | 1.75 (108) | |
| grepafloxacin | 0.66[ | 0.72 (9) | 0.07 (89) | |
| sitafloxacin | −0.16[ | 0.76 (575) | −0.17 (6) | |
| lomefloxacin | −0.47[ | 0.27 (157) | −0.43 (9) | |
| cephalosporins | cefpiramide | 0.95[ | 0.84 (12) | −0.97 (202) |
| cefotetan | 0.31[ | 0.64 (106) | −0.38 (223) | |
| ceforanide | −1.35[ | −1.87 (39) | −3.18 (136) | |
| lincosamides | clindamycin | 0.78[ | 1.76 (126) | 1.04 (33) |
| tazobactam | −1.69[ | −1.33 (21) | −1.4 (17) |
Relative error (%) is reported in parentheses.
Average RMSDs and standard deviations (Å) between the DFT and molecular mechanics optimized geometries for the classes of antimicrobial compounds included in AB-DB.
| Family | Mean ± STD |
|---|---|
| aminocoumarins | 0.4 ± 0.1 |
| aminoglycosides | 0.3 ± 0.1 |
| anthracyclines | 0.4 ± 0.1 |
| beta-lactamase-inhibitors | 0.3 ± 0.2 |
| carbapenems | 0.5 ± 0.2 |
| cephalosporins | 0.6 ± 0.2 |
| dhfr-inhibitors | 0.4 ± 0.2 |
| efflux-pumps-inhibitors | 0.4 ± 0.2 |
| fusidanes | 0.4 ± 0.1 |
| lincosamides | 0.4 ± 0.2 |
| macrolides | 0.4 ± 0.1 |
| monobactams | 0.6 ± 0.1 |
| nucleosides | 0.6 ± 0.2 |
| oxacephem | 0.5 ± 0.1 |
| oxazolidinones | 0.4 ± 0.1 |
| penicillins | 0.5 ± 0.2 |
| phenicols | 0.5 ± 0.1 |
| quinolones | 0.3 ± 0.1 |
| rifamycins | 0.5 ± 0.1 |
| streptogramins | 0.6 ± 0.0 |
| sulphonamides | 0.6 ± 0.3 |
| tetracyclines | 0.4 ± 0.3 |
| others | 0.3 ± 0.2 |
| Measurement(s) | molecular physical property analysis objective |
| Technology Type(s) | Computer Modeling |